Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症
A disease of the motor neurons that control movement, leading to progressive muscle weakness.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 194
- cities
- 57
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 13% of the world's English-language research papers on amyotrophic lateral sclerosis, 2021–2025 (7% in 2016–2020), and 6% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
194 hospitals in 57 cities
Order: papers led on amyotrophic lateral sclerosis, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 1 papers or 1 trial on amyotrophic lateral sclerosis, or was a site in 1 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens amyotrophic lateral sclerosis in that city. 47 more cities are in the menu below.
- 60 papers ledNo open trial led
- 52 papers led
- 44 papers ledNo open trial led
- 23 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 14 papers ledNo open trial led
- 13 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 47
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 65 papers led3 hospitals
- 60 papers led3 hospitals
- 51 papers led2 hospitals
- 33 papers led3 hospitals
- 24 papers led1 hospital
- 22 papers led2 hospitals
- 20 papers led1 hospital
- 20 papers led2 hospitals
- 18 papers led3 hospitals
- 15 papers led1 hospital
- 14 papers led6 hospitals
- 14 papers led3 hospitals
- 13 papers led2 hospitals
- 13 papers led4 hospitals
- 12 papers led4 hospitals
- 10 papers led5 hospitals
- 8 papers led2 hospitals
- 8 papers led2 hospitals
- 7 papers led3 hospitals
- 7 papers led3 hospitals
- 7 papers led1 hospital
- 7 papers led2 hospitals
- 6 papers led1 hospital
- 6 papers led2 hospitals
- 6 papers led2 hospitals
- 6 papers led2 hospitals
- 5 papers led2 hospitals
- 5 papers led3 hospitals
- 5 papers led1 hospital
- 5 papers led4 hospitals
- 4 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led1 hospital
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led0 hospitals
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led0 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 1 paper led1 hospital
open trials on amyotrophic lateral sclerosis in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 13 Nov 2026, with at least one listed hospital as lead sponsor or site, and at least one listed hospital's site marked open. 5 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingTP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Registry
- NCT06726577
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou
- RecruitingThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06765499
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingResearch on Wireless Brain Implant System for General Control of External Devices
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06829212
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06849609
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Registry
- NCT07082192
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingThe Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07118319
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06556394
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou
- RecruitingClinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06671236
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingClinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
- Phase
- N/A
- Started
- 2024-03
- Registry
- NCT06765564
Age 18 years to 60 years (registered criteria)
Led by Shanghai East Hospital, Tongji University; 1 listed hospital as study siteShanghai
- RecruitingClinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- Phase
- Phase 4
- Started
- 2023-01
- Registry
- NCT05923905
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingChina Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine
- Phase
- Not given
- Started
- 2021-03
- Registry
- NCT04885374
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Registered Cohort Study on Amyotrophic Lateral Sclerosis
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04008329
Age not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingNatural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- Phase
- Not given
- Started
- 2019-11
- Registry
- NCT04454892
Age not stated (registered criteria)
Led by Peking University Third HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
Where these numbers come from
Papers
779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 13 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.